Aspen Pharma Group in the news

Aspen Pharmacare's stock is near its 52-week high, with investors scrutinizing earnings and dividends to justify the current valuation.

Aspen Pharmacare Holdings Limited achieved its FY 2026 strategic goals with strong growth in Commercial Pharmaceuticals, a significantly strengthened balance sheet due to a major divestment, and declared a dividend of 232 cents per share.

Stephen Saad built Aspen Pharmacare from selling medicine in townships to a global pharmaceutical company through strategic acquisitions and a focus on affordable healthcare, culminating in a major asset sale in 2026.

Aspen Pharmacare Canada secured Health Canada approval for Aspen-Semaglutide, a generic alternative to Ozempic ® for treating adults with type 2 diabetes.

Aspen Pharmacare Holdings is undergoing significant board changes, facing flat revenue and losses despite a stock price target increase and being deemed undervalued.

Aspen Pharmacare Canada received Health Canada approval for Aspen-Semaglutide, a generic equivalent of Ozempic, for treating adults with type 2 diabetes.

Aspen Pharmacare Canada received Health Canada approval for a generic version of Ozempic®, called ᴾʳAspen-Semaglutide, for type 2 diabetes treatment in adults.

Aspen Pharmacare Canada received Health Canada approval for its generic equivalent of Ozempic® (semaglutide injection) for adults with type 2 diabetes.

Aspen Pharmacare's shares are rebounding due to strategic restructuring, an R26.5 billion asset sale, and improved governance, despite weaker interim earnings.

Aspen Pharmacare Holdings Limited is Africa's leading pharmaceutical group, specializing in treatments for various diseases and operating 24 production sites globally.

Aspen Pharmacare announced that Chairman Kuseni Dlamini will step down in December 2026, to be succeeded by Ben Kruger.

Insider transactions at Aspen Pharmacare Holdings showed net buying over the past year, with a key advisor making a significant purchase, indicating insider confidence despite recent losses.

Aspen Pharmacare is experiencing oral contraceptive shortages in South Africa after decommissioning an unprofitable local factory in favor of imported alternatives.

Aspen Pharmacare is focusing on high-margin sterile manufacturing and global emerging markets to drive long-term specialty pharmaceutical growth.

Allens advised BGH Capital on its USD1.6 billion acquisition of Aspen Pharmacare's Asia-Pacific business, covering subsidiaries and IP assets across several countries.

Aspen Pharmacare's share price jumped 7% after completing a R27 billion divestment of its Asia Pacific operations to reduce debt.

Aspen Pharmacare completed the $1.65 billion sale of its Asia Pacific business, reducing debt and increasing Stephen Saad's net worth.

Aspen Pharmacare is reporting revenue growth driven by its sterile injectables and hospital-focused specialty medicine portfolios across emerging markets.

Specializes in manufacturing and distributing essential branded and generic pharmaceuticals across emerging markets and Europe.

Aspen Pharmacare maintains steady growth through low-cost generics manufacturing and strong demand in emerging markets, supported by vertical integration and a solid balance sheet.